Results 231 to 240 of about 4,218,282 (383)

Mitochondria‐associated membranes (MAMs): molecular organization, cellular functions, and their role in health and disease

FEBS Open Bio, EarlyView.
Mitochondria‐associated membranes (MAMs) are contact sites between the endoplasmic reticulum and mitochondria that regulate calcium signaling, lipid metabolism, autophagy, and stress responses. This review outlines their molecular organization, roles in cellular homeostasis, and how dysfunction drives neurodegeneration, metabolic disease, cancer, and ...
Viet Bui, Maryline Santerre, Natalia Shcherbik, Bassel E Sawaya   +3 more
wiley   +1 more source

European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015)

, 2015
A. Muraro, W.J. Fokkens, S. Pietikainen, D. Borrelli, Ioana Agache, Jean Bousquet, V. Costigliola, G. Joos, V.J. Lund, L.K. Poulsen, D. Price, C. Rolland, Torsten Zuberbier, Peter W. Hellings   +13 more
openalex   +2 more sources

Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine [PDF]

, 2016
Adel Gouri, Aoulia Dekaken, Khalid El Bairi, Arifa Aissaoui, Nihad Laabed, Mohamed Chefrour, Joseph Ciccolini, G. Milano, Sadek Benharkat   +8 more
openalex   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Towards precision medicine

Acta Medica Lituanica, 2017
Sonata Jarmalaitė
doaj  

The Fuzzy World of Precision Medicine: Deliberations of a Precision Medicine Tumor Board [PDF]

, 2016
Sarah McGraw, Judy E. Garber, Pasi A. Jänne, Neal I. Lindeman, Nelly Oliver, Lynette M. Sholl, Eliezer M. Van Allen, Nikhil Wagle, Levi A. Garraway, Steven Joffe, Stacy W. Gray   +10 more
openalex   +1 more source

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

Annals of Oncology, 2022
J. Pascual, G. Attard, F. Bidard, G. Curigliano, L. De Mattos-Arruda, M. Diehn, A. Italiano, J. Lindberg, J. Merker, C. Montagut, N. Normanno, K. Pantel, G. Pentheroudakis, S. Popat, J. Reis-Filho, J. Tie, J. Seoane, N. Tarazona, T. Yoshino, N. Turner   +19 more
semanticscholar   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

Developing precision medicine for people of East Asian descent [PDF]

, 2016
Stacy L. McAllister, Katherine Sun, Eric R. Gross   +2 more
openalex   +1 more source

Artificial intelligence-based multi-omics analysis fuels cancer precision medicine.

Seminars in Cancer Biology, 2022
Xiujing He, Xiaowei Liu, Fengli Zuo, Hubing Shi, Jing Jing   +4 more
semanticscholar   +1 more source